Posted by Michael Wonder on 17 Oct 2022
Calls for TGA to withdraw Covid drug approval
17 October 2022 - The medicines regulator is facing calls to withdraw its provisional approval for the antiviral drug molnupiravir amid concerns at mounting evidence it is ineffective in reducing the risk of severe disease or hospitalisation.
The Therapeutic Goods Administration granted provisional approval for molnupiravir, sold under the brand name Legevrio, in January this year for the treatment of adults with Covid-19 who were at increased risk of hospitalisation or death.
